| GC17592-50mg |
|
142715-48-8 |
|
0 |
C31H36N4O6.HCl |
|
|
|
| GC17592-10mg |
|
142715-48-8 |
|
0 |
C31H36N4O6.HCl |
|
|
|
| GC17591-10mg |
|
123-78-4 |
D-erythro-Sphingosine (synthetic)
|
0 |
C18H37NO2 |
|
|
|
| GC17589-10mg |
|
191936-91-1 |
HIV-1 Tat Protein Peptide
|
0 |
C64H118N32O14 |
|
|
|
| GC17589-1mg |
|
191936-91-1 |
HIV-1 Tat Protein Peptide
|
0 |
C64H118N32O14 |
|
|
|
| GC17588-10mg |
|
19879-32-4 |
|
0 |
C20H20O4 |
|
|
|
| GC17588-5mg |
|
19879-32-4 |
|
0 |
C20H20O4 |
|
|
|
| GC17587-200mg |
|
89226-50-6 |
|
0 |
C35H38N4O6 |
|
|
|
| GC17587-50mg |
|
89226-50-6 |
|
0 |
C35H38N4O6 |
|
|
|
| GC17587-25mg |
|
89226-50-6 |
|
0 |
C35H38N4O6 |
|
|
|
| GC17586-10mM (in 1mL DMSO) |
|
540737-29-9 |
Tofacitinib (CP-690550) Citrate
|
0 |
C16H20N6O.C6H8O7 |
|
|
|
| GC17586-50mg |
|
540737-29-9 |
Tofacitinib (CP-690550) Citrate
|
0 |
C16H20N6O.C6H8O7 |
|
|
|
| GC17586-10mg |
|
540737-29-9 |
Tofacitinib (CP-690550) Citrate
|
0 |
C16H20N6O.C6H8O7 |
|
|
|
| GC17585-50mg |
|
1028327-66-3 |
|
0 |
C15H19N5 |
|
|
|
| GC17585-10mg |
|
1028327-66-3 |
|
0 |
C15H19N5 |
|
|
|
| GC17582-10mM (in 1mL DMSO) |
|
1062368-49-3 |
|
0 |
C22H16N4O |
|
|
|
| GC17582-50mg |
|
1062368-49-3 |
|
0 |
C22H16N4O |
|
|
|
| GC17582-10mg |
|
1062368-49-3 |
|
0 |
C22H16N4O |
|
|
|
| GC17582-5mg |
|
1062368-49-3 |
|
0 |
C22H16N4O |
|
|
|
| GC17580-10mM (in 1mL DMSO) |
|
763113-22-0 |
Olaparib (AZD2281, Ku-0059436)
|
0 |
C24H23FN4O3 |
|
|
|
